Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities

Cell Reports

Volumn 14, Issue 2, 2016, Pages 298-309

  Sanjiv, Kumar ^a   Hagenkort, Anna ^a   Calderón Montaño, José Manuel ^a   Koolmeister, Tobias ^a   Reaper, Philip M ^b   Mortusewicz, Oliver ^a   Jacques, Sylvain A ^a   Kuiper, Raoul V ^a   Schultz, Niklas ^a   Scobie, Martin ^a   Charlton, Peter A ^b   Pollard, John R ^b   Berglund, Ulrika Warpman ^a   Altun, Mikael ^a   Helleday, Thomas ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; ATR PROTEIN; CHECKPOINT KINASE 1; HISTONE H2AX; PROTEIN SERINE THREONINE KINASE INHIBITOR; SINGLE STRANDED DNA; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VE 821; VX 970; ATM PROTEIN; ATR PROTEIN, HUMAN; PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SPECIFIC SYNTHETIC LETHALITY; CELLULAR PARAMETERS; CONTROLLED STUDY; DNA DAMAGE; DNA REPLICATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG TUMOR; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; REPLICATION STRESS; S PHASE CELL CYCLE CHECKPOINT; TUMOR XENOGRAFT; GENETICS; METABOLISM; TUMOR CELL LINE;

APOPTOSIS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CELL LINE, TUMOR; CHECKPOINT KINASE 1; DNA DAMAGE; HUMANS; PROTEIN KINASES;

EID: 84955384250     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.12.032     Document Type: Article

References (53)

1. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Aparicio S.A., Behjati S., Biankin A.V., Bignell G.R., Bolli N., Borg A., Børresen-Dale A.L., et al. Signatures of mutational processes in human cancer. Nature 2013, 500:415-421. Australian Pancreatic Cancer Genome Initiative, ICGC Breast Cancer ConsortiumICGC Breast Cancer Consortium, ICGC MMML-Seq ConsortiumICGC MMML-Seq Consortium, ICGC PedBrainICGC PedBrain.
2. Aris S.M., Pommier Y. Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762. Cancer Res. 2012, 72:979-989.
3. Bartkova J., Horejsí Z., Koed K., Krämer A., Tort F., Zieger K., Guldberg P., Sehested M., Nesland J.M., Lukas C., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
4. Bartkova J., Rezaei N., Liontos M., Karakaidos P., Kletsas D., Issaeva N., Vassiliou L.V., Kolettas E., Niforou K., Zoumpourlis V.C., et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444:633-637.
5. Bester A.C., Roniger M., Oren Y.S., Im M.M., Sarni D., Chaoat M., Bensimon A., Zamir G., Shewach D.S., Kerem B. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell 2011, 145:435-446.
6. Brooks K., Oakes V., Edwards B., Ranall M., Leo P., Pavey S., Pinder A., Beamish H., Mukhopadhyay P., Lambie D., Gabrielli B. A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress. Oncogene 2013, 32:788-796.
7. Buisson R., Boisvert J.L., Benes C.H., Zou L. Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase. Mol. Cell 2015, 59:1011-1024.
8. Choi S., Toledo L.I., Fernandez-Capetillo O., Bakkenist C.J. CGK733 does not inhibit ATM or ATR kinase activity in H460 human lung cancer cells. DNA Repair (Amst.) 2011, 10:1000-1001. author reply 1002.
9. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70:440-446.
10. Cimprich K.A., Cortez D. ATR: an essential regulator of genome integrity. Nat. Rev. Mol. Cell Biol. 2008, 9:616-627.
11. Couch F.B., Bansbach C.E., Driscoll R., Luzwick J.W., Glick G.G., Bétous R., Carroll C.M., Jung S.Y., Qin J., Cimprich K.A., Cortez D. ATR phosphorylates SMARCAL1 to prevent replication fork collapse. Genes Dev. 2013, 27:1610-1623.
12. de Feraudy S., Revet I., Bezrookove V., Feeney L., Cleaver J.E. A minority of foci or pan-nuclear apoptotic staining of gammaH2AX in the S phase after UV damage contain DNA double-strand breaks. Proc. Natl. Acad. Sci. USA 2010, 107:6870-6875.
13. Di Micco R., Fumagalli M., Cicalese A., Piccinin S., Gasparini P., Luise C., Schurra C., Garre' M., Nuciforo P.G., Bensimon A., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444:638-642.
14. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., Sougnez C., Greulich H., Muzny D.M., Morgan M.B., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
15. Elvers I., Hagenkort A., Johansson F., Djureinovic T., Lagerqvist A., Schultz N., Stoimenov I., Erixon K., Helleday T. CHK1 activity is required for continuous replication fork elongation but not stabilization of post-replicative gaps after UV irradiation. Nucleic Acids Res. 2012, 40:8440-8448.
16. Feijoo C., Hall-Jackson C., Wu R., Jenkins D., Leitch J., Gilbert D.M., Smythe C. Activation of mammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing. J. Cell Biol. 2001, 154:913-923.
17. Fokas E., Prevo R., Pollard J.R., Reaper P.M., Charlton P.A., Cornelissen B., Vallis K.A., Hammond E.M., Olcina M.M., Gillies McKenna W., et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis. 2012, 3:e441.
18. Foote K.M., Blades K., Cronin A., Fillery S., Guichard S.S., Hassall L., Hickson I., Jacq X., Jewsbury P.J., McGuire T.M., et al. Discovery of 4-4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. J. Med. Chem. 2013, 56:2125-2138.
19. Foote K.M., Lau A., Nissink J.W. Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer. Future Med. Chem. 2015, 7:873-891.
20. Gabay M., Li Y., Felsher D.W. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb. Perspect. Med. 2014, 4:a014241.
21. Gad H., Koolmeister T., Jemth A.S., Eshtad S., Jacques S.A., Ström C.E., Svensson L.M., Schultz N., Lundbäck T., Einarsdottir B.O., et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature 2014, 508:215-221.
22. Gagou M.E., Zuazua-Villar P., Meuth M. Enhanced H2AX phosphorylation, DNA replication fork arrest, and cell death in the absence of Chk1. Mol. Biol. Cell 2010, 21:739-752.
23. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., Venere M., Ditullio R.A., Kastrinakis N.G., Levy B., et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434:907-913.
24. Groth P., Ausländer S., Majumder M.M., Schultz N., Johansson F., Petermann E., Helleday T. Methylated DNA causes a physical block to replication forks independently of damage signalling, O(6)-methylguanine or DNA single-strand breaks and results in DNA damage. J. Mol. Biol. 2010, 402:70-82.
25. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature 1999, 400:464-468.
26. Halazonetis T.D., Gorgoulis V.G., Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008, 319:1352-1355.
27. Hekmat-Nejad M., You Z., Yee M.C., Newport J.W., Cimprich K.A. Xenopus ATR is a replication-dependent chromatin-binding protein required for the DNA replication checkpoint. Curr. Biol. 2000, 10:1565-1573.
28. Hills S.A., Diffley J.F. DNA replication and oncogene-induced replicative stress. Curr. Biol. 2014, 24:R435-R444.
29. Höglund A., Nilsson L.M., Muralidharan S.V., Hasvold L.A., Merta P., Rudelius M., Nikolova V., Keller U., Nilsson J.A. Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells. Clin. Cancer Res. 2011, 17:7067-7079.
30. Huntoon C.J., Flatten K.S., Wahner Hendrickson A.E., Huehls A.M., Sutor S.L., Kaufmann S.H., Karnitz L.M. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res. 2013, 73:3683-3691.
31. Jiang H., Reinhardt H.C., Bartkova J., Tommiska J., Blomqvist C., Nevanlinna H., Bartek J., Yaffe M.B., Hemann M.T. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 2009, 23:1895-1909.
32. Jones R.M., Mortusewicz O., Afzal I., Lorvellec M., García P., Helleday T., Petermann E. Increased replication initiation and conflicts with transcription underlie Cyclin E-induced replication stress. Oncogene 2013, 32:3744-3753.
33. Jossé R., Martin S.E., Guha R., Ormanoglu P., Pfister T.D., Reaper P.M., Barnes C.S., Jones J., Charlton P., Pollard J.R., et al. ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014, 74:6968-6979.
34. Luciani M.G., Oehlmann M., Blow J.J. Characterization of a novel ATR-dependent, Chk1-independent, intra-S-phase checkpoint that suppresses initiation of replication in Xenopus. J. Cell Sci. 2004, 117:6019-6030.
35. Ma C.X., Janetka J.W., Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol. Med. 2011, 17:88-96.
36. Mitchell J.B., Choudhuri R., Fabre K., Sowers A.L., Citrin D., Zabludoff S.D., Cook J.A. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin. Cancer Res. 2010, 16:2076-2084.
37. Murga M., Bunting S., Montaña M.F., Soria R., Mulero F., Cañamero M., Lee Y., McKinnon P.J., Nussenzweig A., Fernandez-Capetillo O. A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging. Nat. Genet. 2009, 41:891-898.
38. Murga M., Campaner S., Lopez-Contreras A.J., Toledo L.I., Soria R., Montaña M.F., D'Artista L., Schleker T., Guerra C., Garcia E., et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat. Struct. Mol. Biol. 2011, 18:1331-1335.
39. Nam E.A., Cortez D. ATR signalling: more than meeting at the fork. Biochem. J. 2011, 436:527-536.
40. Petermann E., Orta M.L., Issaeva N., Schultz N., Helleday T. Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair. Mol. Cell 2010, 37:492-502.
41. Petermann E., Woodcock M., Helleday T. Chk1 promotes replication fork progression by controlling replication initiation. Proc. Natl. Acad. Sci. USA 2010, 107:16090-16095.
42. Reaper P.M., Griffiths M.R., Long J.M., Charrier J.D., Maccormick S., Charlton P.A., Golec J.M., Pollard J.R. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. 2011, 7:428-430.
43. Rohban S., Campaner S. Myc induced replicative stress response: How to cope with it and exploit it. Biochim. Biophys. Acta 2015, 1849:517-524.
44. Sørensen C.S., Hansen L.T., Dziegielewski J., Syljuåsen R.G., Lundin C., Bartek J., Helleday T. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat. Cell Biol. 2005, 7:195-201.
45. Syljuåsen R.G., Sørensen C.S., Hansen L.T., Fugger K., Lundin C., Johansson F., Helleday T., Sehested M., Lukas J., Bartek J. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol. Cell. Biol. 2005, 25:3553-3562.
46. Tang Y., Hamed H.A., Poklepovic A., Dai Y., Grant S., Dent P. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors. Mol. Pharmacol. 2012, 82:322-332.
47. Toledo L.I., Murga M., Fernandez-Capetillo O. Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs. Mol. Oncol. 2011, 5:368-373.
48. Toledo L.I., Altmeyer M., Rask M.B., Lukas C., Larsen D.H., Povlsen L.K., Bekker-Jensen S., Mailand N., Bartek J., Lukas J. ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell 2013, 155:1088-1103.
49. Wilsker D., Petermann E., Helleday T., Bunz F. Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control. Proc. Natl. Acad. Sci. USA 2008, 105:20752-20757.
50. Yang X.H., Shiotani B., Classon M., Zou L. Chk1 and Claspin potentiate PCNA ubiquitination. Genes Dev. 2008, 22:1147-1152.
51. Zabludoff S.D., Deng C., Grondine M.R., Sheehy A.M., Ashwell S., Caleb B.L., Green S., Haye H.R., Horn C.L., Janetka J.W., et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol. Cancer Ther. 2008, 7:2955-2966.
52. Zhao H., Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol. Cell. Biol. 2001, 21:4129-4139.
53. Zou L., Elledge S.J. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 2003, 300:1542-1548.